Skip to main content

Staphylococcus Aureus Bacteremia

3
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Ceftobiprole medocarilPhase 31 trial
Active Trials
NCT03138733Completed390Est. Mar 2022
iNtRON Biotechnology
iNtRON BiotechnologyKorea - Gyeonggi
1 program
1
N-Rephasin® SAL200Phase 21 trial
Active Trials
NCT03089697Terminated25Est. Nov 2019
Armata Pharmaceuticals
Armata PharmaceuticalsLOS ANGELES, CA
1 program
1
AP-SA02Phase 1/21 trial
Active Trials
NCT05184764Completed56Est. Jan 2025
Design Therapeutics
1 program
Follow recommendations based on scientific evidence to S. aureus bacteremia managementN/A1 trial
Active Trials
NCT01971762Completed600Est. Jan 2012
Design Pharmaceuticals
1 program
Follow recommendations based on scientific evidence to S. aureus bacteremia managementN/A
XBiotech
XBiotechAUSTIN, TX
1 program
514G3PHASE_1_21 trial
Active Trials
NCT02357966Completed52Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesCeftobiprole medocaril
iNtRON BiotechnologyN-Rephasin® SAL200
Armata PharmaceuticalsAP-SA02
XBiotech514G3
Design TherapeuticsFollow recommendations based on scientific evidence to S. aureus bacteremia management

Clinical Trials (5)

Total enrollment: 1,123 patients across 5 trials

NCT03138733Human BioSciencesCeftobiprole medocaril

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Start: Aug 2018Est. completion: Mar 2022390 patients
Phase 3Completed
NCT03089697iNtRON BiotechnologyN-Rephasin® SAL200

Phase IIa Clinical Study of N-Rephasin® SAL200

Start: Mar 2017Est. completion: Nov 201925 patients
Phase 2Terminated
NCT05184764Armata PharmaceuticalsAP-SA02

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Start: Apr 2022Est. completion: Jan 202556 patients
Phase 1/2Completed
NCT02357966XBiotech514G3

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

Start: May 2015Est. completion: Dec 201652 patients
Phase 1/2Completed
NCT01971762Design TherapeuticsFollow recommendations based on scientific evidence to S. aureus bacteremia management

Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology

Start: Apr 2011Est. completion: Jan 2012600 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.